Function Matters: Variant Mechanisms in the Era of Precision Medicine

• References

• 1 Oliver KL, Scheffer IE, Bennett MF, Grinton BE, Bahlo M, Berkovic SF. Genes4Epilepsy: an epilepsy gene resource. Epilepsia 2023; 64 (05) 1368-1375
• 2 Ruggiero SM, Xian J, Helbig I. The current landscape of epilepsy genetics: where are we, and where are we going?. Curr Opin Neurol 2023; 36 (02) 86-94
• 3 Wojcik MH, Larkin K, Cipicchio M. et al. Toward same-day genome sequencing in the critical care setting. N Engl J Med 2025; NEJMc2512825
• 4 eClinical Medicine. Whole-genome sequencing for every newborn in the UK: promise and practicalities. EClinicalMedicine 2025; 85: 103387
• 5 Beltrán-Corbellini Á, Aledo-Serrano Á, Møller RS. et al. Epilepsy genetics and precision medicine in adults: a new landscape for developmental and epileptic encephalopathies. Front Neurol 2022; 13: 777115
• 6 Knowles JK, Helbig I, Metcalf CS. et al. Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges, and suggestions for continued progress. Epilepsia 2022; 63 (10) 2461-2475
• 7 Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics 2020; 17 (02) 609-615
• 8 Wolff M, Johannesen KM, Hedrich UBS. et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain 2017; 140 (05) 1316-1336
• 9 Absalom NL, Liao VWY, Johannesen KMH. et al. Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nat Commun 2022; 13 (01) 1822
• 10 Johannesen KM, Liu Y, Koko M. et al. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain 2022; 145 (09) 2991-3009